Table 3.

Antibiotic Susceptibility Profiles of Carbapenem-Resistant Klebsiella pneumoniae Isolates from Selected Long-Term Acute Care Hospitals, January 2014 to March 2015

AntibioticNo. of Isolates TestedSusceptible,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Amikacin885298 (33.7)63 (7.1)524 (59.2)
Ciprofloxacin63010 (1.6)2 (0.3)618 (98.1)
Levofloxacin71312 (1.7)3 (0.4)698 (97.9)
Gentamicin or tobramycin63011 (1.7)3 (0.5)616 (97.8)
Colistin or polymyxin B690579 (83.9)0 (0)111 (16.1)
Tigecycline439413 (94.1)23 (5.2)3 (0.7)
AntibioticNo. of Isolates TestedSusceptible,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Amikacin885298 (33.7)63 (7.1)524 (59.2)
Ciprofloxacin63010 (1.6)2 (0.3)618 (98.1)
Levofloxacin71312 (1.7)3 (0.4)698 (97.9)
Gentamicin or tobramycin63011 (1.7)3 (0.5)616 (97.8)
Colistin or polymyxin B690579 (83.9)0 (0)111 (16.1)
Tigecycline439413 (94.1)23 (5.2)3 (0.7)
Table 3.

Antibiotic Susceptibility Profiles of Carbapenem-Resistant Klebsiella pneumoniae Isolates from Selected Long-Term Acute Care Hospitals, January 2014 to March 2015

AntibioticNo. of Isolates TestedSusceptible,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Amikacin885298 (33.7)63 (7.1)524 (59.2)
Ciprofloxacin63010 (1.6)2 (0.3)618 (98.1)
Levofloxacin71312 (1.7)3 (0.4)698 (97.9)
Gentamicin or tobramycin63011 (1.7)3 (0.5)616 (97.8)
Colistin or polymyxin B690579 (83.9)0 (0)111 (16.1)
Tigecycline439413 (94.1)23 (5.2)3 (0.7)
AntibioticNo. of Isolates TestedSusceptible,
n (%)
Intermediate,
n (%)
Resistant,
n (%)
Amikacin885298 (33.7)63 (7.1)524 (59.2)
Ciprofloxacin63010 (1.6)2 (0.3)618 (98.1)
Levofloxacin71312 (1.7)3 (0.4)698 (97.9)
Gentamicin or tobramycin63011 (1.7)3 (0.5)616 (97.8)
Colistin or polymyxin B690579 (83.9)0 (0)111 (16.1)
Tigecycline439413 (94.1)23 (5.2)3 (0.7)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close